Thursday, December 15, 2005

SIPO allows RegeneRx Drug Patent

RegeneRx Biopharmaceuticals, Inc. has received notification that the State Intellectual Property Office of the People's Republic of China (SIPO) has allowed its first patent application for the Company's Thymosin beta 4 (TB4), wound healing technology platform.

RegeneRx president and CEO J.J. Finkelstein: "We are very pleased to be advancing our intellectual property portfolio in this important market. China, of course, represents one of the largest and fastest growing pharmaceutical markets in the world; we look forward to receiving additional patents in China in the future and addressing a number of potential opportunities in that market."

Read here more.

No comments: